European Journal of Gastroenterology & Hepatology最新文献

{"title":"Clinical characteristics and long-term outcomes among inflammatory bowel disease patients of different ethnic groups: a case-control study.","authors":"Nour Ealiwa, Waleed Alamour, Muhammad Abu-Tailakh, Lior Eraki, Heba Abu-Kaf, Sarah Weissmann, Naim Abu-Freha","doi":"10.1097/MEG.0000000000003047","DOIUrl":"10.1097/MEG.0000000000003047","url":null,"abstract":"<p><strong>Introduction: </strong>Inflammatory bowel disease (IBD) causes chronic inflammation in the gastrointestinal tract, particularly in the colon and small intestine. We aimed to compare the clinical characteristics and long-term outcomes of Arab Bedouin and Jewish IBD patients in the Negev.</p><p><strong>Methods: </strong>This retrospective case-control study (1:2 matching, controlled for age and sex) included patients of Bedouin Arab (BA) or Jewish origin, aged 18 or older, diagnosed with Crohn's disease (CD) or ulcerative colitis (UC). Data on demographics, disease behavior, outcomes, and mortality were collected.</p><p><strong>Results: </strong>One hundred sixty-seven CD patients and 159 UC patients were included. Fifty-eight (34.7%) of the CD patients and 53 (33.3%) of the UC patients were BA. BA CD patients had a higher proportion of ileal disease (56.9 vs. 35.8%, P  = 0.009), and lower healthcare utilization, including fewer emergency department visits (9.4 ± 8.7 vs. 16.2 ± 13.8, P  < 0.001) and fewer hospitalizations (5.18 ± 6 vs. 12.2 ± 12, P  < 0.001) than Jewish patients. Treatment disparities showed that AB patients were less likely to receive biological therapies (55.2 vs. 84.4%, P  < 0.001). Regarding UC, AB patients had a higher rate of proctitis than Jewish patients (56.6 vs. 29.2%, P  < 0.001) and a higher rate of extraintestinal manifestations 41.5 vs. 11.3%, P  < 0.001, respectively. In addition, BA UC patients had a lower rate of biological treatment but a higher rate of hospitalization and death.</p><p><strong>Conclusion: </strong>The study underscores the need for tailored healthcare strategies for BA IBD patients, including improved healthcare access, financial and social support, and culturally sensitive educational initiatives.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of the American Society for Gastrointestinal Endoscopy, European Society of Gastrointestinal Endoscopy, and Society of American Gastrointestinal and Endoscopic Surgeons criteria in predicting common bile duct microlithiasis.","authors":"Yufang Cui, Jun Li, Qiming Huang, Jianglong Hong, Suwen Li, Lihong Chen, Junjun Bao, Qiao Mei","doi":"10.1097/MEG.0000000000003037","DOIUrl":"10.1097/MEG.0000000000003037","url":null,"abstract":"<p><strong>Background: </strong>Patients with suspected common bile duct stones are classified as high risk (HR), intermediate risk (IR), or low risk (LR) based on the American Society for Gastrointestinal Endoscopy (ASGE), European Society of Gastrointestinal Endoscopy (ESGE), and Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). This study validated common bile duct microlithiasis (CBDM) clinical risk stratification utility.</p><p><strong>Methods: </strong>We retrospectively reviewed cases of suspected CBDM between November 2017 and May 2024. After liver function tests, ultrasound or computed tomography, all patients were stratified according to ASGE, ESGE, and SAGES into HR, IR, and LR.</p><p><strong>Results: </strong>Among 269 HR patients, diagnostic accuracy was 61.71% [95% confidence interval (CI): 55.77-67.32] for ASGE, 60.59% (95% CI: 54.65-66.25) for ESGE, and 56.51% (95% CI: 50.53-62.30) for SAGES. In the IR group, CBDM confirmation by endoscopic ultrasound (EUS) or magnetic resonance cholangiopancreatography (MRCP) revealed: under ASGE (n = 108), E US detected CBDM in 52 (no stones: 13) vs. MRCP identified CBDM in 19 (negative: 46), yielding 36.5% sensitivity; for ESGE (n = 93), EUS identified CBDM in 46 (no stones:9) vs. MRCP identified CBDM in 32 (negative: 25) at 69.6% sensitivity; per SAGES (n = 69), in the 43 receiving both modalities, EUS detected CBDM in 37 (no stones: 6) vs. MRCP detected CBDM in 14 (negative: 29) with 37.8% sensitivity.</p><p><strong>Conclusion: </strong>We validated ASGE, ESGE, and SAGES for CBDM prediction but found suboptimal. EUS demonstrates superior sensitivity over MRCP for IR evaluation.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144882497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcutaneous electrical nerve stimulation therapy for intractable childhood constipation: a clinical observational and comparative study.","authors":"Ilke Aktas, Nevzat Aykut Bayrak, Rabia Gönül Sezer Yamanel","doi":"10.1097/MEG.0000000000003039","DOIUrl":"https://doi.org/10.1097/MEG.0000000000003039","url":null,"abstract":"<p><strong>Purpose: </strong>To determine the efficacy of transcutaneous electrical nerve stimulation (TENS) on children with intractable constipation and compare treatment success between TENS application twice weekly and three times weekly.</p><p><strong>Methods: </strong>We recruited otherwise healthy consecutive children aged 6-17 years old suffering from intractable constipation over a 6-month period. Anatomic causes and organic pathologies were ruled out. All children received TENS treatment for 20 min, during 4 weeks, three times a week in group 1 and twice a week in group 2 for 4 weeks. Patients were evaluated for defecation frequency, stool consistency, symptom relief, and fecal incontinence before, at the first week, at the end, and 4 weeks after treatment was discontinued.</p><p><strong>Results: </strong>Twenty patients were enrolled in group 1 and 15 in group 2. Age, gender, and duration of constipation were indifferent among groups. After treatment, there was a significant increase in the number of weekly defecations (P < 0.001), improvement in fecal incontinence (P < 0.05), and painful defecation (P < 0.001) in both groups; however, each group's improvements did not persist 4 weeks after the treatment's discontinuation (P > 0.05). Meanwhile, twice weekly TENS was as effective as three-times weekly TENS (P > 0.05).</p><p><strong>Conclusion: </strong>TENS treatment appears to improve weekly defecation, fecal incontinence, and pain in children with intractable constipation; however, effects are not sustained after discontinuation. The twice-weekly and three-times weekly protocols yielded comparable results; however, the study lacked sufficient power to conclusively demonstrate noninferiority.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum metabolites and gut microbiota mediate the causal link between anxiety and nonalcoholic fatty liver disease: a Mendelian randomization analysis.","authors":"Siyao Wang, Xinyi Liu, Jia He, Yihan Cui, Ai Jia","doi":"10.1097/MEG.0000000000003043","DOIUrl":"https://doi.org/10.1097/MEG.0000000000003043","url":null,"abstract":"<p><strong>Background: </strong>Nonalcoholic fatty liver disease (NAFLD) is defined by liver fat accumulation exceeding 5% in individuals who do not consume significant amounts of alcohol. This condition can advance to more severe outcomes, including fibrosis, cirrhosis, and liver cancer. Although numerous factors contribute to the progression of NAFLD, the influence of psychological elements, especially anxiety, remains inadequately explored.</p><p><strong>Methods: </strong>This study applied Mendelian randomization (MR) using genome-wide association data from 4761 NAFLD cases and 373 227 controls to investigate the causal relationship between psychological factors and NAFLD. We conducted both multivariable and mediation MR analyses to determine how anxiety influences NAFLD through pathways involving gut microbiota and metabolites. Furthermore, we examined datasets related to anxiety and NAFLD from the Gene Expression Omnibus, identified differentially expressed genes, and conducted enrichment analyses on the genes shared between these two conditions.</p><p><strong>Results: </strong>The MR analysis established a direct causal relationship between genetically predicted anxiety and the development of NAFLD (β=0.229, 95% confidence interval = 1.11-1.41, P = 0.0002). This association was confirmed by multivariable MR, independent of BMI and type 2 diabetes. Mediation MR revealed that specific metabolites and fatty acid-related gut microbiota mediate the relationship between anxiety and NAFLD. Additionally, enrichment analysis confirmed the involvement of fatty acids in genes common to both anxiety and NAFLD.</p><p><strong>Conclusion: </strong>This study suggests that genetically predicted anxiety contributes to the development of NAFLD by influencing specific gut microbiota and metabolites, underscoring the vital role of mental health in mitigating NAFLD risk.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy and safety of endoscopic submucosal resection in periappendiceal lesions: a systematic review and meta-analysis.","authors":"Hazem Abosheaishaa, Abdellatif Ismail, Mohanad Awadalla, Shaikhoon Mohammed, Monzer Abdalla, Ayman Elawad, Chukwunonso Ezeani, Jenson Phung, Mohamed Abdallah, Neil Nero, Amit Bhatt, Madhusudhan Sanaka, Mohammad Bilal","doi":"10.1097/MEG.0000000000003042","DOIUrl":"10.1097/MEG.0000000000003042","url":null,"abstract":"<p><strong>Introduction: </strong>Endoscopic submucosal dissection (ESD) is a promising technique for early-stage gastrointestinal neoplasms; however, its use for periappendiceal lesions poses challenges because of anatomical complexities and the potential risk of appendicitis or perforation. As a result, these lesions are often managed surgically. This systematic review and meta-analysis evaluate the safety and efficacy of ESD for periappendiceal lesions.</p><p><strong>Methodology: </strong>A systematic search across multiple databases was conducted, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eligible studies focused on adult populations undergoing ESD for periappendiceal lesions. The primary outcome was a technical success, and secondary outcomes included R0 resection, en-bloc resection, adverse events, and need for surgery. Data were reported using percentages with associated confidence intervals (CIs) and heterogeneity (I²).</p><p><strong>Results: </strong>Six studies comprising 298 patients were included. Technical success was achieved in 98% (95% CI: 97-100%, I2 : 4.63%), with R0 resection and en-bloc resection rates of 84% (95% CI: 77-91%, I2 : 61.86%) and 92% (95% CI: 86-97%, I2 : 66.11%), respectively. The overall rates of polyp recurrence, appendicitis, and bleeding were 0.1% (95% CI: 0-2%, I2 : 0%), 3% (95% CI: 0-4%, I2 : 0%), and 1% (95% CI: 0-3%, I2 : 0%), respectively. Conversely, perforation exhibited a relatively high incidence of 11% (95% CI: 3-19%, I2 : 84.55%); however, the need for surgical intervention was 6% (95% CI: 1-10%, I2 : 74.12%).</p><p><strong>Conclusion: </strong>ESD provides a safe and effective alternative to surgical resection for managing periappendiceal lesions.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential effects of sleep duration on cardiovascular risk in metabolic-associated fatty liver disease vs. without metabolic-associated fatty liver disease: evidence from National Health and Nutrition Examination Survey and Mendelian randomization.","authors":"Siyao Wang, Xinyi Liu, Jia He, Yihan Cui, Ai Jia","doi":"10.1097/MEG.0000000000003040","DOIUrl":"10.1097/MEG.0000000000003040","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular disease (CVD) risk increases in patients with metabolic-associated fatty liver disease (MAFLD). While sleep duration is linked to CVD risk, it is unclear whether it differs between individuals with and without MAFLD.</p><p><strong>Methods: </strong>Data from the National Health and Nutrition Examination Survey (2007-2020; n = 10 386) were analyzed using multivariable logistic regression to examine the relationship between sleep duration and CVD. Subgroup analyses and a restricted cubic spline model assessed interactions and potential nonlinear associations, while Mendelian randomization (MR) was used to infer causality.</p><p><strong>Results: </strong>Long sleep duration (≥9 h) was associated with an increased CVD risk in MAFLD patients [P = 0.005, odds ratio (OR) = 1.92, 95% confidence intervals (CI): 1.22-3.02], while short sleep duration (≤6 h) was linked to a higher CVD risk in non-MAFLD individuals (P = 0.030, OR = 1.63, 95% CI: 1.05-2.52). Subgroup analysis revealed that marital status modified this association in MAFLD patients. A U-shaped relationship was observed, with the lowest CVD risk occurring at 6.7 h of sleep for MAFLD patients and 7.9 h for non-MAFLD individuals. MR suggested a causal link (P = 0.03, OR = 1.42, 95% CI: 1.02-1.97), with the results remaining robust after adjusting for potential confounders.</p><p><strong>Conclusion: </strong>Long sleep duration increases CVD risk in MAFLD patients, with a U-shaped relationship indicating the lowest risk at 6.7 h of sleep in MAFLD and 7.9 h in non-MAFLD individuals. MR analysis suggests a causal link between sleep duration and CVD.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tegoprazan vs. proton pump inhibitors for erosive esophagitis: a superior alternative or just another option? A systematic review and meta-analysis of randomized controlled trials.","authors":"Muhammad Anas Nayyer, Hamna Rasool, Hassan Murtaza, Muhammad Rehman Safdar, Suchna Meeral Khan, Salman Khalid, Mohammad Umer","doi":"10.1097/MEG.0000000000003030","DOIUrl":"10.1097/MEG.0000000000003030","url":null,"abstract":"<p><p>Tegoprazan, a novel potassium-competitive acid blocker, has emerged as a potential alternative to proton pump inhibitors (PPIs) for the treatment of erosive esophagitis (EE), especially in light of long-term safety concerns associated with PPIs. This study aimed to assess the efficacy and safety of tegoprazan compared to PPIs in patients with EE. A systematic review and meta-analysis were conducted following preferred reporting items for systematic reviews and meta-analyses guidelines, including three randomized controlled trials with a total of 658 patients diagnosed with EE. The primary outcomes were cumulative endoscopic healing rates across 4-8 weeks and at 4 and 8 weeks, while secondary outcomes included any adverse events, drug-related treatment-emergent adverse events (TEAEs), and serious adverse events (SAEs). Tegoprazan demonstrated noninferior healing rates at 4 weeks [relative risk (RR) = 1.05, 95% confidence interval (CI): 0.96-1.16; P = 0.28; I² = 51%] and 8 weeks (RR = 1.01, 95% CI: 0.96-1.06; P = 0.73; I² = 0%) compared to PPIs. There was no statistically significant difference in the overall incidence of adverse events or SAEs (RR = 1.19, 95% CI: 0.92-1.53; P = 0.19; I² = 24%). However, a significantly higher rate of drug-related TEAEs was observed in the tegoprazan group (RR = 1.23, 95% CI: 1.03-1.48; P = 0.02; I² = 0%). In conclusion, tegoprazan is an effective treatment option for EE, with comparable efficacy to PPIs, though further studies are warranted to evaluate its long-term safety before routine clinical use.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Home-based transcutaneous electrical acupuncture-point stimulation for depressive symptoms in inflammatory bowel disease: a randomized feasibility study.","authors":"Chongwen Huang, Wladyslawa Czuber-Dochan, Christine Norton","doi":"10.1097/MEG.0000000000003034","DOIUrl":"10.1097/MEG.0000000000003034","url":null,"abstract":"<p><strong>Background: </strong>Depressive symptoms are common in individuals with inflammatory bowel disease (IBD) and are associated with poor disease outcomes. Transcutaneous electrical acupuncture point stimulation (TEAS) is a noninvasive intervention with potential benefits for inflammation but remains untested in IBD. We developed a smartphone application for home-based TEAS self-administration and evaluated its feasibility, acceptability, and preliminary effects.</p><p><strong>Methods: </strong>In a randomized feasibility study, IBD patients with Patient Health Questionnaire-9 (PHQ-9) scores ≥ 8 were recruited through Crohn's and Colitis UK. Participants were remotely trained to use the TEAS device, locate acupoints, and self-administer the treatment via the app. Group A completed 30-min daily sessions for 21 days from week 1, while Group B started in week 6. Outcomes [recruitment, retention, acceptability, depression, fatigue, pain, and quality of life (QoL)] were assessed at baseline, week 4, and week 9.</p><p><strong>Results: </strong>Of the 109 individuals of interest, 57 were assessed, 37 were eligible, and 36 were randomized. In Group A, 83% (15/18) completed ≥ 18 sessions, compared to 50% (9/18) in Group B. The questionnaire completion rates were 92% ( n  = 33) at baseline, 83% ( n  = 30) at 4 weeks, and 67% ( n  = 24) at 9 weeks. Most participants (81%) recommended TEAS. Preliminary analysis showed reduced depressive symptoms and improved QoL postintervention and at the follow-up. Postintervention, the mean PHQ-9 score decreased from 13.9 to 7.7 in Group A and from 14.2 to 6.5 in Group B.</p><p><strong>Conclusions: </strong>Home-based TEAS is feasible, acceptable, and has a clinical potential. A full-scale randomized controlled trial is needed to confirm its efficacy in the treatment of IBD-related depression.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polygenic risk of refractory celiac disease type II and its association with autoimmune diseases: a phenome-wide association study in the UK Biobank.","authors":"Lampriani Tsali, Konstantinos Tsilidis, Konstantinos Katsanos, Evangelia Ntzani, Maria Manou, Christopher Papandreou, Georgios Markozannes, Christos V Chalitsios","doi":"10.1097/MEG.0000000000003036","DOIUrl":"10.1097/MEG.0000000000003036","url":null,"abstract":"<p><strong>Objective: </strong>Refractory celiac disease-type II (RCDII) is the more severe and adverse form of celiac disease; however, its association with other autoimmune diseases remains unclear. We conducted a phenome-wide association study (PheWAS) to examine the association between the polygenic risk score (PRS) for RCDII and autoimmune diseases.</p><p><strong>Methods: </strong>To construct the PRS-RCDII, we extracted summary statistics for three non-human leukocyte antigen genetic variants, which were independently associated with RCDII (r2 < 0.001; P < 5 × 10-5) in a genome-wide association study. We then conducted a PRS-PheWAS in the UK Biobank to investigate the associations of PRS-RCDII with 27 autoimmune diseases, adjusting for age, sex, genetic batch, and genetic ancestry. False discovery rate (FDR < 0.05) correction was applied to account for multiple comparisons.</p><p><strong>Results: </strong>Our study population comprised 373 022 UK Biobank participants (mean age: 57.2 years), of whom 202 865 (54.4%) were females. We constructed the PRS-RCDII, using three genetic variants, namely rs2041570 on chromosome 7p14.3 (FAM188B), rs7324708 on chromosome 13q22.1 (KLF12), and rs205047 on chromosome 17p12 (SHISA6). In the PRS-PheWAS, two phenotypes were initially associated with RCDII at a nominal P value threshold, ankylosing spondylitis and systemic sclerosis; however, after adjusting for multiple comparisons, only the association with ankylosing spondylitis remained statistically significant (odds ratioper 1 SD increase = 1.13; 95% confidence interval: 1.04-1.22; PFDR = 0.023). Sex-stratified and single-nucleotide polymorphism (SNP)-by-SNP analyses revealed no significant heterogeneity.</p><p><strong>Conclusion: </strong>Our study identified an association between the genetic risk score for RCDII and ankylosing spondylitis, but not with other autoimmune diseases. This finding may have clinical importance for people with RCDII, although replication in future studies is needed.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of vessels encapsulating tumor clusters patterns in hepatocellular carcinoma: a literature review.","authors":"Miaomiao Wang, Yinzhong Wang, Ya Shen, Liang Cao, Ruifeng Yan, Junqiang Lei","doi":"10.1097/MEG.0000000000003032","DOIUrl":"https://doi.org/10.1097/MEG.0000000000003032","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is one of the most common and highly lethal tumors worldwide. Early metastasis is the main cause of postoperative recurrence and high mortality in patients with HCC. Vessels encapsulating tumor clusters (VETCs) are a distinct vascular metastatic pattern different from microvascular invasion, which has higher recurrence and mortality rates because of its unique metastatic mechanism; however, VETC is currently recognized only by the morphological manifestations of pathology, while in-depth understanding and discussion are insufficient. In future clinical practice, VETC patterns may have a nonnegligible role in the prediction of HCC, therapeutic decision-making, and are closely related to the long-term survival and management of patients. In addition, there is unlimited research potential regarding the mechanism of VETC patterns. This paper summarizes VETC-positive HCC based on pathogenesis, diagnosis, prognosis, and treatment, and discusses current limitations and future prospects.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144590783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}